<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260107068587N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-01-27</date_registration>
      <primary_sponsor>Rah-e Zendegi Psychological Clinics, affiliated with the Imam Khomeini Relief Foundation (IRF)</primary_sponsor>
      <public_title>Effect of a Neurophenomenological Intervention on Social Anxiety in Adolescents</public_title>
      <acronym>NATB</acronym>
      <scientific_title>Neurophenomenological Transformation in Adolescents with Social Anxiety Disorder: Comparing the Effectiveness of a Neural–Embodied Regulation Intervention versus Another Therapeutic Intervention in Improving Interoceptive Markers</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-01-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>38</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88709</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: This study is a single-arm interventional clinical trial with a pretest–posttest design in which all eligible participants will receive the neurophenomenological neural–embodied regulation intervention delivered in an 8-session protocol. Primary outcomes, including interoceptive markers and social anxiety severity, will be assessed at baseline and after completion of the intervention. In addition, a qualitative component will be conducted to explore participants’ lived experiences of bodily and emotional changes throughout the treatment process.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Adolescent Social Anxiety Disorder.</hc_freetext>
      <i_freetext>Intervention group: An individual, face-to-face autonomic regulation psychotherapy based on Polyvagal Theory and Somatic Experiencing for adolescents with Social Anxiety Disorder. This intervention is delivered at the “Rah-e Zendegi” psychology clinics and consists of eight structured therapeutic sessions. Each session lasts 60 minutes and is provided over a 3-week period (three sessions per week). A 6-month follow-up assessment will also be conducted after completion of the intervention.Session content includes:(1) establishing safety and therapeutic alliance with initial psychoeducation about threat and safety responses;(2) enhancing interoceptive awareness and identifying bodily anxiety signals;(3) grounding exercises and body-based attentional regulation;(4) autonomic arousal regulation with gradual exposure to age-appropriate social situations;(5) working with threat responses through controlled oscillation between tension and calm states (pendulation);(6) therapist–client co-regulation and relational repair;(7) integrating felt safety into social interactions through body-based interpersonal exercises; and(8) review, consolidation, and relapse-prevention planning.In selected sessions, brief video-assisted recall is used to facilitate embodied reflection on lived experience and bodily changes. The intervention is delivered by trained psychotherapists under supervision. Treatment fidelity is monitored using a standardized checklist, and a randomly selected subset of sessions is reviewed by an independent supervisor. This study includes no pharmacological intervention or consumable substance..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Due to the sensitive psychological and physiological data collected from adolescents and the need to protect participant confidentiality, there is no plan to publicly share individual participant data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parvaneh Rahmati Sangkar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 4, Second Floor, No. 3, Mazaheri Street, Narmak Square 38, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۶۸۱۹۴۶۵۱۴</zip>
        <telephone>+98 21 2390 2489</telephone>
        <email>parvanehrahmati1383@gmail.com</email>
        <affiliation>Imam Khomeini Relief Foundation</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parvaneh Rahmati Sangkar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 4, Second Floor, No. 3, Mazaheri Street, Narmak Square 38, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۶۸۱۹۴۶۵۱۴</zip>
        <telephone>+98 21 2390 2489</telephone>
        <email>parvanehrahmati1383@gmail.com</email>
        <affiliation>Imam Khomeini Relief Foundation</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Formal diagnosis of Social Anxiety Disorder based on DSM-5 criteria using the MINI-KID interview
Score of 25 or higher on the Social Anxiety subscale of the SCARED questionnaire
Score of 3 or higher on the Pubertal Development Scale as an indicator of entry into the target developmental stage
Willingness to participate in the treatment program and adherence until completion of the 8-session protocol
No use of psychotropic medications during the past 6 months</inclusion_criteria>
      <agemin>13 years</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of psychotic disorders
Moderate to severe neurodevelopmental disorders
Confirmed substance use or substance use disorder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F40.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Social phobias</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: An individual, face-to-face autonomic regulation psychotherapy based on Polyvagal Theory and Somatic Experiencing for adolescents with Social Anxiety Disorder. This intervention is delivered at the “Rah-e Zendegi” psychology clinics and consists of eight structured therapeutic sessions. Each session lasts 60 minutes and is provided over a 3-week period (three sessions per week). A 6-month follow-up assessment will also be conducted after completion of the intervention.Session content includes:(1) establishing safety and therapeutic alliance with initial psychoeducation about threat and safety responses;(2) enhancing interoceptive awareness and identifying bodily anxiety signals;(3) grounding exercises and body-based attentional regulation;(4) autonomic arousal regulation with gradual exposure to age-appropriate social situations;(5) working with threat responses through controlled oscillation between tension and calm states (pendulation);(6) therapist–client co-regulation and relational repair;(7) integrating felt safety into social interactions through body-based interpersonal exercises; and(8) review, consolidation, and relapse-prevention planning.In selected sessions, brief video-assisted recall is used to facilitate embodied reflection on lived experience and bodily changes. The intervention is delivered by trained psychotherapists under supervision. Treatment fidelity is monitored using a standardized checklist, and a randomly selected subset of sessions is reviewed by an independent supervisor. This study includes no pharmacological intervention or consumable substance.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heart rate variability (HRV) as an index of autonomic nervous system regulation, measured by resting RMSSD. Timepoint: Baseline (pre-test; week 0)Post-intervention (post-test; week 3)6-month follow-up after completion of the intervention (approximately week 26). Method of measurement: Heart rate variability is recorded using the BioPac MP150 physiological recording system with a finger photoplethysmography sensor, and the root mean square of successive differences of beat-to-beat intervals is extracted from resting recordings.</prim_outcome>
      <prim_outcome>Skin conductance level (electrodermal activity) as an index of sympathetic autonomic arousal. Timepoint: Baseline (pre-test; week 0); end of intervention (post-test; week 3); 6-month follow-up after the intervention (approximately week 26). Method of measurement: Skin conductance level will be measured using the BioPac MP150 physiological recording system with silver/silver chloride surface electrodes.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Severity of social anxiety symptoms based on the social anxiety subscale score of the Screen for Child and Adolescent Anxiety Related Emotional Disorders questionnaire (SCARED; Birmaher et al., 1999). Timepoint: Baseline (pre-test; week 0); end of intervention (post-test; week 3); six-month follow-up after the intervention (approximately week 26). Method of measurement: Screen for Child and Adolescent Anxiety Related Emotional Disorders questionnaire (SCARED; Birmaher et al., 1999), social anxiety subscale.</sec_outcome>
      <sec_outcome>Severity of social avoidance based on the social avoidance subscale score of the Screen for Child and Adolescent Anxiety Related Emotional Disorders questionnaire (SCARED; Birmaher et al., 1999). Timepoint: Baseline (pre-test; week 0); end of intervention (post-test; week 3); six-month follow-up after the intervention (approximately week 26). Method of measurement: Screen for Child and Adolescent Anxiety Related Emotional Disorders questionnaire (SCARED; Birmaher et al., 1999), social avoidance subscale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rah-e Zendegi Psychological Clinics, affiliated with the Imam Khomeini Relief Foundation (IRF)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-05</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University of Medical Sciences, Qom Branch</contact_name>
        <contact_address>15 Khordad Blvd., Islamic Azad University of Medical Sciences, Qom Branch, Qom, Iran Qom Ghoum Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
